Jing Di
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jing Di has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Sainan Wei
Department of Pathology & Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA
4 shared publications - Bin Huang
Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
2 shared publications - Eric B. Durbin
Kentucky Cancer Registry, Markey Cancer Center, University of Kentucky, Lexington, Ky
2 shared publications - Jaclyn K. McDowell
Markey Cancer Center, Cancer Research Informatics Shared Resource Facility, University of Kentucky, Lexington, KY 40536, USA
2 shared publications - Jingjing Hu
Department of Pathology University of California San Diego San Diego California USA
2 shared publications - Leonard N. Yenwongfai
Department of Pathology & Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77778
Global Burden and Temporal Trends of Early‐Onset Tracheal, Bronchial, and Lung Cancer: An Analysis of GLOBOCAN 2022 and GBD 2023 Data
Background Early‐onset tracheal, bronchial, and lung (EOTBL) cancer represents a distinct clinical entity. This study aimed to assess the global burden and temporal trends of EOTBL cancer, focusing on socioeconomic disparities, to inform global cancer control strategies. Methods Using GLOBOCAN 2022 and GBD 2023 data, we analyzed EOTBL cancer incidence, mortality, and attributable risk factors across distinct geographic regions and Human Development Index (HDI) tiers. Findings In 2022, EOTBL cancer caused 137,705 incident cases and 72,646 deaths globally. Eastern Asia showed the highest incidence. Socioeconomically, regions with a High HDI presented the highest incidence burden. However, the Medium‐ and Low‐HDI regions experienced disproportionately high mortality burden. The temporal trends in EOTBL cancer exhibited profound national heterogeneity, closely tied to geography, human development, and sex. Risk profiles varied drastically: active smoking remained the primary driver in countries like Russia, whereas ambient particulate matter pollution emerged as a major determinant in rapidly developing economies like China. Interpretation EOTBL cancer pattern exhibits notable disparities across sex, geographic regions, and HDI levels. Framing effective global policies requires moving beyond generalized interventions toward tailored, region‐specific public health strategies.
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77778
Open AccessGlobal Burden and Temporal Trends of Early‐Onset Tracheal, Bronchial, and Lung Cancer: An Analysis of GLOBOCAN 2022 and GBD 2023 Data
Background Early‐onset tracheal, bronchial, and lung (EOTBL) cancer represents a distinct clinical entity. This study aimed to assess the global burden and temporal trends of EOTBL cancer, focusing on socioeconomic disparities, to inform global cancer control strategies. Methods Using GLOBOCAN 2022 and GBD 2023 data, we analyzed EOTBL cancer incidence, mortality, and attributable risk factors across distinct geographic regions and Human Development Index (HDI) tiers. Findings In 2022, EOTBL cancer caused 137,705 incident cases and 72,646 deaths globally. Eastern Asia showed the highest incidence. Socioeconomically, regions with a High HDI presented the highest incidence burden. However, the Medium‐ and Low‐HDI regions experienced disproportionately high mortality burden. The temporal trends in EOTBL cancer exhibited profound national heterogeneity, closely tied to geography, human development, and sex. Risk profiles varied drastically: active smoking remained the primary driver in countries like Russia, whereas ambient particulate matter pollution emerged as a major determinant in rapidly developing economies like China. Interpretation EOTBL cancer pattern exhibits notable disparities across sex, geographic regions, and HDI levels. Framing effective global policies requires moving beyond generalized interventions toward tailored, region‐specific public health strategies.
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Mediastinum
- Vol. 9, 32
Molecular reprogramming in thymic neuroendocrine tumors: a narrative review
Background and Objective: Thymic neuroendocrine tumors (tNETs) are rare and heterogeneous neoplasms with limited evidence to guide diagnosis and management. Traditional classifications rely heavily on morphology, but recent advances in molecular profiling have begun to reshape understanding of their biology and clinical behavior. This narrative review synthesizes recent molecular findings in tNETs and proposes an integrated framework that combines traditional morphology with molecular stratification to guide precision oncology. Methods: We performed a narrative review of the current literature on tNETs, focusing on histologic classification, molecular taxonomy, diagnostic algorithms, and therapeutic strategies. Special emphasis was placed on integrating emerging evidence from genomic, epigenetic, and clinical studies published between 2010 and 2025. Key Content and Findings: Molecular frameworks such as copy number instability (CNI)-based classification, together with recurrent alterations in MEN1, TP53, and RB1, are refining risk stratification and linking tNETs to neuroendocrine neoplasms in other organ systems. Therapeutic advances include the use of everolimus and temozolomide, while PRRT appears less effective in this subgroup. Epigenetic dysregulation and novel trial designs, including basket and adaptive studies, represent promising avenues for future research. Conclusions: This review integrates current knowledge of tNETs with recent advances in molecular diagnostics and therapeutic strategies. By highlighting key genetic and epigenetic alterations, as well as future directions such as liquid biopsy, artificial intelligence, and novel trial designs, we emphasize the need for biomarker-driven approaches to improve outcomes in this ultra-rare disease.
- 1 December 2025
- Published by AME Publishing Company in Mediastinum
- Vol. 9, 32
Open AccessMolecular reprogramming in thymic neuroendocrine tumors: a narrative review
Background and Objective: Thymic neuroendocrine tumors (tNETs) are rare and heterogeneous neoplasms with limited evidence to guide diagnosis and management. Traditional classifications rely heavily on morphology, but recent advances in molecular profiling have begun to reshape understanding of their biology and clinical behavior. This narrative review synthesizes recent molecular findings in tNETs and proposes an integrated framework that combines traditional morphology with molecular stratification to guide precision oncology. Methods: We performed a narrative review of the current literature on tNETs, focusing on histologic classification, molecular taxonomy, diagnostic algorithms, and therapeutic strategies. Special emphasis was placed on integrating emerging evidence from genomic, epigenetic, and clinical studies published between 2010 and 2025. Key Content and Findings: Molecular frameworks such as copy number instability (CNI)-based classification, together with recurrent alterations in MEN1, TP53, and RB1, are refining risk stratification and linking tNETs to neuroendocrine neoplasms in other organ systems. Therapeutic advances include the use of everolimus and temozolomide, while PRRT appears less effective in this subgroup. Epigenetic dysregulation and novel trial designs, including basket and adaptive studies, represent promising avenues for future research. Conclusions: This review integrates current knowledge of tNETs with recent advances in molecular diagnostics and therapeutic strategies. By highlighting key genetic and epigenetic alterations, as well as future directions such as liquid biopsy, artificial intelligence, and novel trial designs, we emphasize the need for biomarker-driven approaches to improve outcomes in this ultra-rare disease.
- 28 November 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (2) , 100-108
The Validation of Digital PCR–Based Minimal Residual Disease Detection for the Common Mutations in IDH1 and IDH2 Genes in Patients with Acute Myeloid Leukemia
- 28 November 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (2) , 100-108
The Validation of Digital PCR–Based Minimal Residual Disease Detection for the Common Mutations in IDH1 and IDH2 Genes in Patients with Acute Myeloid Leukemia
- Open Access
- 28 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (11) , 2476
Prognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study
Background: This retrospective cohort study investigates the prognostic significance of genetic mutations in Chronic Myelomonocytic Leukemia (CMML) and their association with treatment responses among patients treated at a single institution, juxtaposed with a statewide dataset from Kentucky. Methods: The study includes 51 patients diagnosed with CMML under the World Health Organization criteria from January 2005 to December 2023. It examines their genomic profiles and subsequent survival outcomes. The analysis also categorizes patients into CMML-1 and CMML-2 subtypes and assesses survival differences between transformed and non-transformed cases. Results: Mutations in TET2, ASXL1, and SRSF2 were found to significantly influence survival, establishing their roles as critical prognostic markers. Additionally, the cohort from the University of Kentucky exhibited distinct survival patterns compared to the broader Kentucky state population, suggesting that demographic and treatment-related factors could underlie these variances. Conclusions: This research underscores the pivotal role of targeted genetic profiling in deciphering the progression of CMML and refining therapeutic strategies. The findings emphasize the necessity for advanced genetic screening in managing CMML to better understand individual prognoses and optimize treatment efficacy, thereby offering insights that could lead to personalized treatment approaches.
- 28 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (11) , 2476
Open AccessPrognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study
Background: This retrospective cohort study investigates the prognostic significance of genetic mutations in Chronic Myelomonocytic Leukemia (CMML) and their association with treatment responses among patients treated at a single institution, juxtaposed with a statewide dataset from Kentucky. Methods: The study includes 51 patients diagnosed with CMML under the World Health Organization criteria from January 2005 to December 2023. It examines their genomic profiles and subsequent survival outcomes. The analysis also categorizes patients into CMML-1 and CMML-2 subtypes and assesses survival differences between transformed and non-transformed cases. Results: Mutations in TET2, ASXL1, and SRSF2 were found to significantly influence survival, establishing their roles as critical prognostic markers. Additionally, the cohort from the University of Kentucky exhibited distinct survival patterns compared to the broader Kentucky state population, suggesting that demographic and treatment-related factors could underlie these variances. Conclusions: This research underscores the pivotal role of targeted genetic profiling in deciphering the progression of CMML and refining therapeutic strategies. The findings emphasize the necessity for advanced genetic screening in managing CMML to better understand individual prognoses and optimize treatment efficacy, thereby offering insights that could lead to personalized treatment approaches.
- Open Access
- 7 October 2024
- Published by MDPI AG in Preprints.org
Prognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study
Background: This retrospective cohort study investigates the prognostic significance of genetic mutations in Chronic Myelomonocytic Leukemia (CMML) and their association with treatment responses among patients treated at a single institution, juxtaposed with a statewide dataset from Kentucky. Methods: The study includes 51 patients diagnosed with CMML under the World Health Organization criteria from January 2005 to December 2023. It examines their genomic profiles and subsequent survival outcomes. The analysis also categorizes patients into CMML-1 and CMML-2 subtypes and assesses survival differences between transformed and non-transformed cases. Results: Mutations in TET2, ASXL1, and SRSF2 were found to significantly influence survival, establishing their roles as critical prognostic markers. Additionally, the cohort from the University of Kentucky exhibited distinct survival patterns compared to the broader Kentucky state population, suggesting that demographic and treatment-related factors could underlie these variances. Conclusions: This research underscores the pivotal role of targeted genetic profiling in deciphering the progression of CMML and refining therapeutic strategies. The findings emphasize the necessity for advanced genetic screening in managing CMML to better understand individual prognoses and optimize treatment efficacy, thereby offering insights that could lead to personalized treatment approaches.
- 7 October 2024
- Published by MDPI AG in Preprints.org
Open AccessPrognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study
Background: This retrospective cohort study investigates the prognostic significance of genetic mutations in Chronic Myelomonocytic Leukemia (CMML) and their association with treatment responses among patients treated at a single institution, juxtaposed with a statewide dataset from Kentucky. Methods: The study includes 51 patients diagnosed with CMML under the World Health Organization criteria from January 2005 to December 2023. It examines their genomic profiles and subsequent survival outcomes. The analysis also categorizes patients into CMML-1 and CMML-2 subtypes and assesses survival differences between transformed and non-transformed cases. Results: Mutations in TET2, ASXL1, and SRSF2 were found to significantly influence survival, establishing their roles as critical prognostic markers. Additionally, the cohort from the University of Kentucky exhibited distinct survival patterns compared to the broader Kentucky state population, suggesting that demographic and treatment-related factors could underlie these variances. Conclusions: This research underscores the pivotal role of targeted genetic profiling in deciphering the progression of CMML and refining therapeutic strategies. The findings emphasize the necessity for advanced genetic screening in managing CMML to better understand individual prognoses and optimize treatment efficacy, thereby offering insights that could lead to personalized treatment approaches.
- Open Access
- 1 August 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1709
NSD3::NUTM1 Fusion Sarcoma Mimicking Malignant Peripheral Nerve Sheath Tumor with Prolonged Survival
Nuclear Protein in Testis (NUT)-rearranged tumors comprise predominantly NUT carcinoma but also include certain lymphomas, leukemias, skin appendage tumors, and sarcomas. Although histologically diverse, all are genetically identified by oncogenic rearrangement in the NUTM1 gene. Many fusion partners occur, and NSD3 is NUT carcinoma’s third most common partner. Herein, we present a case of a 26-year-old man with an NSD3::NUTM1 fusion sarcoma. The patient presented at the age of 13 months with a scalp nodule. Over the next 24 years, he experienced five local recurrences and ultimately expired of a rapidly progressive recurrence. His treatment included surgical resections, radiation, and various chemotherapies. Deceptively, the clinical presentation and histopathology aligned with a malignant peripheral nerve sheath tumor, a diagnosis rendered at initial resection with concurrence by a national soft tissue tumor expert. The patient’s exceptionally long survival could be due to NSD3 as the fusion partner, aided by the initial small tumor size and young patient age. Thus, this case expands NUT fusion sarcomas’ histologic and immunohistochemical profile to include mimicking a malignant peripheral nerve sheath tumor (MPNST). Additionally, it indicates that the NSD3::NUTM1 fusion can drive sarcoma genesis.
- 1 August 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1709
Open AccessNSD3::NUTM1 Fusion Sarcoma Mimicking Malignant Peripheral Nerve Sheath Tumor with Prolonged Survival
Nuclear Protein in Testis (NUT)-rearranged tumors comprise predominantly NUT carcinoma but also include certain lymphomas, leukemias, skin appendage tumors, and sarcomas. Although histologically diverse, all are genetically identified by oncogenic rearrangement in the NUTM1 gene. Many fusion partners occur, and NSD3 is NUT carcinoma’s third most common partner. Herein, we present a case of a 26-year-old man with an NSD3::NUTM1 fusion sarcoma. The patient presented at the age of 13 months with a scalp nodule. Over the next 24 years, he experienced five local recurrences and ultimately expired of a rapidly progressive recurrence. His treatment included surgical resections, radiation, and various chemotherapies. Deceptively, the clinical presentation and histopathology aligned with a malignant peripheral nerve sheath tumor, a diagnosis rendered at initial resection with concurrence by a national soft tissue tumor expert. The patient’s exceptionally long survival could be due to NSD3 as the fusion partner, aided by the initial small tumor size and young patient age. Thus, this case expands NUT fusion sarcomas’ histologic and immunohistochemical profile to include mimicking a malignant peripheral nerve sheath tumor (MPNST). Additionally, it indicates that the NSD3::NUTM1 fusion can drive sarcoma genesis.
- Open Access
- 20 July 2024
- Published by Springer Nature in Cureus
- Vol. 16 (7) , e65013
Transition From Epstein-Barr Virus (EBV)-Positive Rectal Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma in the Lung
We report a distinctive case of sequential lymphomas in a 72-year-old male, initially diagnosed with Epstein-Barr virus (EBV)-positive rectal classic Hodgkin lymphoma (cHL), followed by the development of diffuse large B cell lymphoma (DLBCL) in the lung. This rare progression underscores the complexity of lymphomas associated with EBV infection and their unpredictable clinical courses. The patient's journey began with symptoms of intractable diarrhea, low appetite, and significant weight loss, leading to the diagnosis of stage 4B cHL, managed initially with brentuximab/doxorubicin, vinblastine, dacarbazine (AVD) chemotherapy. Despite a partial response, surveillance identified a transition to DLBCL, marked by new pulmonary lesions. This case highlights the clinical and diagnostic challenges in managing sequential lymphomas, emphasizing the role of EBV in lymphomagenesis and the potential for clonal evolution from a common precursor cell. The therapeutic approach evolved from targeted chemotherapy to consideration of advanced treatments such as autologous stem cell transplant and chimeric antigen receptor (CAR) T-cell therapy, reflecting the aggressive nature and poor prognosis of the disease. This case contributes to our understanding of the EBV's impact on lymphoma progression and underscores the need for vigilant monitoring and adaptive treatment strategies in similar clinical scenarios.
- 20 July 2024
- Published by Springer Nature in Cureus
- Vol. 16 (7) , e65013
Open AccessTransition From Epstein-Barr Virus (EBV)-Positive Rectal Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma in the Lung
We report a distinctive case of sequential lymphomas in a 72-year-old male, initially diagnosed with Epstein-Barr virus (EBV)-positive rectal classic Hodgkin lymphoma (cHL), followed by the development of diffuse large B cell lymphoma (DLBCL) in the lung. This rare progression underscores the complexity of lymphomas associated with EBV infection and their unpredictable clinical courses. The patient's journey began with symptoms of intractable diarrhea, low appetite, and significant weight loss, leading to the diagnosis of stage 4B cHL, managed initially with brentuximab/doxorubicin, vinblastine, dacarbazine (AVD) chemotherapy. Despite a partial response, surveillance identified a transition to DLBCL, marked by new pulmonary lesions. This case highlights the clinical and diagnostic challenges in managing sequential lymphomas, emphasizing the role of EBV in lymphomagenesis and the potential for clonal evolution from a common precursor cell. The therapeutic approach evolved from targeted chemotherapy to consideration of advanced treatments such as autologous stem cell transplant and chimeric antigen receptor (CAR) T-cell therapy, reflecting the aggressive nature and poor prognosis of the disease. This case contributes to our understanding of the EBV's impact on lymphoma progression and underscores the need for vigilant monitoring and adaptive treatment strategies in similar clinical scenarios.
- Open Access
Familial 4p Interstitial Deletion Provides New Insights and Candidate Genes Underlying This Rare Condition
Chromosome 4p deletions can lead to two distinct phenotypic outcomes: Wolf-–Hirschhorn syndrome (a terminal deletion at 4p16.3) and less frequently reported proximal interstitial deletions (4p11-p16). Proximal 4p interstitial deletions can result in mild to moderate intellectual disability, facial dysmorphisms, and a tall thin body habitus. To date, only 35 cases of proximal 4p interstitial deletions have been reported, and only two of these cases have been familial. The critical region for this syndrome has been narrowed down to 4p15.33-15.2, but the underlying causative genes remain unclear. In this study, we report the case of a 3-year-old female with failure to thrive, developmental and motor delays, and morphological features. The mother also had a 4p15.2-p14 deletion, and the proband was found to have a 13.4-Mb 4p15.2-p14 deletion by chromosome microarray analysis. The deleted region encompasses 16 genes, five of which have a high likelihood of contributing to the phenotype: PPARGC1A, DHX15, RBPJ, STIM2, and PCDH7. These findings suggest that multiple genes are involved in this rare proximal 4p interstitial deletion syndrome. This case highlights the need for healthcare providers to be aware of proximal 4p interstitial deletions and the potential phenotypic manifestations.
Open AccessFamilial 4p Interstitial Deletion Provides New Insights and Candidate Genes Underlying This Rare Condition
Chromosome 4p deletions can lead to two distinct phenotypic outcomes: Wolf-–Hirschhorn syndrome (a terminal deletion at 4p16.3) and less frequently reported proximal interstitial deletions (4p11-p16). Proximal 4p interstitial deletions can result in mild to moderate intellectual disability, facial dysmorphisms, and a tall thin body habitus. To date, only 35 cases of proximal 4p interstitial deletions have been reported, and only two of these cases have been familial. The critical region for this syndrome has been narrowed down to 4p15.33-15.2, but the underlying causative genes remain unclear. In this study, we report the case of a 3-year-old female with failure to thrive, developmental and motor delays, and morphological features. The mother also had a 4p15.2-p14 deletion, and the proband was found to have a 13.4-Mb 4p15.2-p14 deletion by chromosome microarray analysis. The deleted region encompasses 16 genes, five of which have a high likelihood of contributing to the phenotype: PPARGC1A, DHX15, RBPJ, STIM2, and PCDH7. These findings suggest that multiple genes are involved in this rare proximal 4p interstitial deletion syndrome. This case highlights the need for healthcare providers to be aware of proximal 4p interstitial deletions and the potential phenotypic manifestations.
- Open Access
- 23 May 2022
- Published by Elsevier in Human Pathology Reports
- Vol. 28
Primitive non-neural granular cell tumor: Literature review
- 23 May 2022
- Published by Elsevier in Human Pathology Reports
- Vol. 28
Open AccessPrimitive non-neural granular cell tumor: Literature review